Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zosano and Lilly agree to develop ZP-PTH product candidate for osteoporosis
The company has also completed a Phase II trial of ZP-PTH to treat severe osteoporosis as well as intends to carry out Phase III development. As part of
The company has also completed a Phase II trial of ZP-PTH to treat severe osteoporosis as well as intends to carry out Phase III development. As part of
Since 1998, Priftin has been approved in combination with one or more antituberculosis drugs, to treat active pulmonary TB caused by Mycobacterium tuberculosis. The approval was based in
The drug is now approved to treat these mCRPC patients who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically
The company intends to create a branded ingredient technology that will be introduced in early 2015 and will target the immune support and sport nutrition markets. After the
The company said that shipments of the product to its pharmacy customers have already started. Pennsaid (diclofenac sodium topical solution) 1.5% w/w is indicated to treat signs and
The US firm is focused on bringing new medicines for patients with central nervous system (CNS) disorders. With the acquisition, Otsuka will have access to Avanir’s clinical development
REOLYSIN’s primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF,
This multicenter, Phase 2 clinical trial enrolled patients who have not responded well to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea®. Top line
If approved, the latest regulatory submission will expand the indications for Imbruvica to a third type of blood cancer. Cilag, a Janssen Pharmaceutical member, and Pharmacyclics Switzerland are
Tarextumab is currently being evaluated in combination with chemotherapy in patients with previously untreated, extensive stage SCLC. The randomized, placebo-controlled Phase II trial will compare progression-free survival (PFS)